Xenetic Biosciences reports Q1 2024 net loss of $1.2M; cash at $7.8M

Xenetic Biosciences, Inc.

2024-Q1 EPS reported -$0.78 revenue$510,817

Net loss of approximately $1.2M for Q1 2024; R&D expenses up 58.6% to $0.9M on DNase preclinical work.
Ended quarter with $7.8M cash; advancing DNase oncology program towards Phase 1 for solid tumors.
Expects multiple preclinical data readouts in H2 2024 to guide clinical development strategy.
G&A expenses decreased 9.8% to $0.8M compared to prior year quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xenetic Biosciences, Inc. reported first quarter of 2024 results: net income Net loss for the quarter ended March 31, 2024 was approximately $1.2 million..

Period: first quarter of 2024
Net income: Net loss for the quarter ended March 31, 2024 was approximately $1.2 million.
Result: reported results

Exact text from the filing

On May 10, 2024, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended March 31, 2024 and providing a business update.

View on SEC.gov

1048 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-003192

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.